The development of novel and selective p56lck tyrosine kinase inhibitors.

Bullington, J L; Cameron, J C; Davis, J E; Dodd, J H; Harris, C A; Henry, J R; Pellegrino-Gensey, J L; Rupert, K C; Siekierka, J J

Bullington, J L; Cameron, J C; Davis, J E; Dodd, J H; Harris, C A; Henry, J R; Pellegrino-Gensey, J L; Rupert, K C; Siekierka, J J.

Affiliation

Bullington JL; R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ 08869, USA.

Bioorg Med Chem Lett ; 8(18): 2489-94, 1998 Sep 22.

Article in En | MEDLINE | ID: mdl-9873567

ABSTRACT

ABSTRACT

Early T-cell receptor mediated signal transduction involves the activation of several tyrosine protein kinases. One of these tyrosine kinases, p56lck, is expressed primarily in T-cells and Natural Killer (NK) cells and has been shown to be critical for their proliferative and effector functions. Indandiones have been identified as a potent and selective chemical class that inhibits p56lck.

Subject(s)

Enzyme Inhibitors/chemical synthesis; Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/antagonists & inhibitors; CSK Tyrosine-Protein Kinase; Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors; Enzyme Activation; Enzyme Inhibitors/pharmacology; Indans/chemistry; Indans/pharmacology; Killer Cells, Natural/enzymology; Models, Chemical; Protein-Tyrosine Kinases/antagonists & inhibitors; Signal Transduction; T-Lymphocytes/enzymology; src-Family Kinases

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / Enzyme Inhibitors Language: En Journal: Bioorg Med Chem Lett Journal subject: BIOQUIMICA / QUIMICA Year: 1998 Document type: Article Affiliation country: United States

Search on Google

Add to My VHL

XML

PubMed Links